Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays

Vos, John De; Thykjær, Thomas; Tarte, Karin; Ensslen, Matthias; Raynaud, P; Requirand, Guilhem; Pellet, Florence; Pantesco, Véronique; Rème, Thierry; Jourdan, Michel; Rossi, Jean‐François; Ørntoft, Torben F.; Klein, Bernard

doi:10.1038/sj.onc.1205868

Cited by 156 publications

(133 citation statements)

References 46 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Alterations in CDC34 protein levels therefore correlate with changes in mRNA levels. These findings are consistent with a previous study suggesting that CDC34 is upregulated in malignant versus normal plasma cells (De Vos et al, 2002). Moreover, higher levels of CDC34 transcripts have also been reported in acute lymphoblastic leukemia and hepatocellular carcinomas (Tanaka et al, 2001).…”

supporting

confidence: 82%

See 1 more Smart Citation

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341

Chauhan

Hideshima

et al. 2004

Oncogene

View full text Add to dashboard Cite

The ubiquitin-conjugating enzyme CDC34 (UBC3) is linked to cell cycle progression in diverse cell types; however, its role in multiple myeloma (MM) pathogenesis is unclear. Here, we show that CDC34 is highly expressed in patient MM cells and MM cell lines versus normal cells. Blocking CDC34 using a dominant-negative strategy enhances the anti-MM activity of Bortezomib/ Proteasome inhibitor PS-341, dexamethasone (Dex) and 2-Methoxyestradiol (2ME2). The expression of wild-type CDC34 reduces Dex-induced cytotoxicity in MM cells. Moreover, inhibition of CDC34 enzymatic activity abrogates interleukin-6-induced protection against Dexinduced apoptosis. Together, these findings provide evidence that (1) CDC34 expression is associated with growth and survival of MM cells and (2) blocking CDC34 activity not only enhances anti-MM activity of Bortezomib and 2ME2 but also overcomes IL-6-triggered Dexresistance.

show abstract

supporting

confidence: 82%

“…Another study using oligonucleotide arrays demonstrated that CDC34 mRNA is highly expressed in malignant versus normal plasma cells (De Vos et al, 2002). To date, however, the functional significance of CDC34 in multiple myeloma (MM) cells also remains undefined.…”

mentioning

confidence: 99%

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341

Chauhan

Hideshima

et al. 2004

Oncogene

View full text Add to dashboard Cite

show abstract

“…In a survey of human breast cancers, CDP/Cux expression was found to be significantly increased in high-grade carcinomas and was inversely correlated with survival. Microarray analysis also revealed that CUTL1 was one of the most up-regulated genes in malignant plasma cells from multiple myelomas (12). The multiple roles of CDP/Cux in cell proliferation, motility, and invasion suggest that it may be involved in both tumor growth and tumor progression.…”

Section: Discussionmentioning

confidence: 99%

The p110 Isoform of the CDP/Cux Transcription Factor Accelerates Entry into S Phase

Sansregret

Goulet

Harada

et al. 2006

Molecular and Cellular Biology

View full text Add to dashboard Cite

show abstract

“…Gene expression profiling of patients with MM and MGUS has revealed well-defined mRNA expression patterns (De Vos et al, 2002;Zhan et al, 2002;Davies et al, 2003). However, while MGUS and MM plasma cells can be distinguished from normal plasma cells, they are difficult to differentiate from each other.…”

Section: Angiogenic-related Genes In Multiple Myelomamentioning

confidence: 99%

Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma

2006

View full text Add to dashboard Cite

Tumor microenvironment is essential for tumor cell proliferation, angiogenesis, invasion and metastasis through its provision of survival signals, secretion of growth and pro-angiogenic factors, and direct adhesion molecule interactions. This review examines its importance in the induction of an angiogenic response in multiple myeloma (MM). The encouraging results of preclinical and clinical trials in which MM has been treated by targeting the tumor microenvironment are also discussed.

show abstract

Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays

Cited by 156 publications

References 46 publications

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341

The p110 Isoform of the CDP/Cux Transcription Factor Accelerates Entry into S Phase

Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma

Contact Info

Product

Resources

About